MAGEA3 and non-small cell lung carcinoma: In combination with an appropriate adjuvant, MAGE-A3 has been clinically tested in NSCLC patients.70 The phase III trial MAGRIT in surgically resected NSCLC patients that are MAGE-A3 positive did not show an increase in PFS compared to the placebo and therefore further research has been stopped.40